In a separate study, an implant containing a different investigational endothelin antagonist (PER-001) reduced macular ...

This was the stock's third consecutive day of losses.

Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.38 per share dividend for the third quarter of 2025. The dividend will be paid on September 12, 2025, to all stockholders ...

Amgen (NASDAQ:AMGN) today announced that it will report its second quarter 2025 financial results on Tuesday, August 5, 2025, after the close of the U.S. financial markets. The announcement will be ...

The Subject Expert Committee (SEC) under the Analgesic and Rheumatology division of the Central Drugs Standard Control ...

Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Amgen (AMGN), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the ...

On July 24, 2025, the PTO Acting Director Coke Morgan Stewart discretionarily denied Amgen’s IPR2025-00601 and IPR2025-00602 challenging ...

Kissei Pharmaceutical is paying Viridian Therapeutics $70 million upfront for Japanese rights to a pair of thyroid eye ...

With a $5 billion investment, the 3,000-employee campus leads biomanufacturing innovation while embracing AI, education and ...

In a recently-issued Director Discretionary Denial decision, U.S. Patent and Trademark Office (USPTO) Acting Director Coke ...

Pharmaceutical stocks slumped after President Donald Trump sent letters to 17 drugmakers with an ultimatum to reduce drug ...

Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...